Liver cancer drug combo shows promise but study halted early
NCT ID NCT05199285
First seen Jun 27, 2026 · Last updated Aug 05, 2026 · Updated 2 times
Summary
This study tested whether two immunotherapy drugs, nivolumab and ipilimumab, could shrink tumors in people with advanced liver cancer that had already been treated with another drug combination. The trial enrolled 15 adults whose cancer had spread or could not be removed by surgery. The study was terminated early, so results are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BCLC STAGE B HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903, United States
-
University of Alabama- Birmingham
Birmingham, Alabama, 35233, United States
-
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida, 33136, United States
-
Vanderbilt University/Ingram Cancer Center
Nashville, Tennessee, 37232, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an IDO1 inhibitor boost immunotherapy against liver cancer?
- AI takes on liver cancer: could a computer help pick the right immunotherapy?
- 3D MRI scan may predict liver cancer treatment success
- New scan could spot hidden cancer left behind after liver surgery
- 3D liver stiffness scan could predict surgery risks
- Immunotherapy combo tested against untreatable liver cancer